A 38-year old female presented to her gynecologist with abdominal distension, abdominal pain, fullness after eating, and increased urination frequency for 2 months
Pelvic examination revealed a suspicious mass on the left ovary
Laboratory findings:
CA-125: 785 U/ml
Genetic testing forBRCA1/2, negative
CT with contrast of the pelvis, abdomen, and chest indicated widespread peritoneal lesions
She was referred to gynecologic oncology and underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking; She had diffuse studding in the omentum and diaphragmatic surfaces
Stage 3C ovarian cancer
She achieved complete removal of gross residual disease (R0)
The patient was started on therapy with carboplatin and every-3-weekly paclitaxel
October 2016
Post-treatment assessment revealed no evidence of disease
March 2017
Patient complained of fatigue and chest pain
Physical examination:
Lungs, moist rales bilaterally
Abdomen, shifting dullness
Laboratory findings: CA-125: 1,052 U/ml
CT imaging: left-sided pleural effusion and sclerotic lesions in the lung apical region, ascites, new hypodense lesions in the right lobe of the liver and enlarged retroperitoneal nodes were considered metastatic
She was started on therapy with weekly paclitaxel and bevacizumab
Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.